News coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.6707621495367 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s analysis:

AMAG Pharmaceuticals (NASDAQ AMAG) traded down $0.15 during mid-day trading on Friday, reaching $14.00. The company had a trading volume of 450,049 shares, compared to its average volume of 1,040,000. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $36.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.

A number of research firms recently issued reports on AMAG. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, August 10th. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.00.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact AMAG Pharmaceuticals (AMAG) Stock Price” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-amag-pharmaceuticals-amag-stock-price.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Insider Buying and Selling by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.